Statement Before the Science Board to the Food and Drug Administration Regarding Opioid Drug Products
If today’s meeting is more than a public relations effort for the Food and Drug Administration (FDA) to show that it is concerned about opioids, then maybe the FDA will listen to the Science Board. The board needs to let the FDA know that the Risk Evaluation and Mitigation Strategy (REMS) programs for opioids require an overhaul. Prescriber education will be ineffective unless past misinformation is explicitly and forcefully corrected.